Recent preclinical studies have expanded the therapeutic landscape by demonstrating that targeting TNF-α or its downstream pathways such as STAT3 and CSF-1 can significantly reduce tumor growth and metastatic potential [11,57]. This evidence concerns the gene STAT3 and neoplasm.